Alligator Bioscience Ab · OMXSTO:ATORX
Alligator Bioscience Ab — Investor Presentation (January 2018)
25 slides from Alligator Bioscience Ab's investor presentation, Jan 30, 2018
Slide 1: Alligator Bioscience AB (publ)
ALLIGATOR BIOSCIENCE AB (PUBL) 30 January 2018 Per Norlén, CEO 1
Slide 2: Disclaimer
Disclaimer FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that provide Alligator’s expectations or forecasts of future events such as new product developments, regulatory approvals and financial performance. Such forward looking statements are subject to risks, unce
Slide 3: Alligator Bioscience in brief
Alligator Bioscience in brief • Swedish clinical-stage biotech company with approx. 50 employees • Pioneers in tumor-directed immunotherapy of cancer • Strategic partnership with Janssen in 2015, total deal value USD 695 million • Listed on Nasdaq Stockholm (2016) mid cap segment (ATORX) • Market ca
Slide 4: Milestones and company history
Milestone payment from Janssen Positive Phase I data ADC-1013 USD 6 million milestone received in January Gererally well tolerated at clinically relevant doses 2018 Organization strengthened New management team members appointed Preclinical development ATOR-1017 2017 Initiation of cell-line developm
Slide 5: Rapid uptake of immuno-oncology
Rapid uptake of immuno-oncology Sales of existing immuno-oncology treatments Market potential for immuno-oncology US$ Million Annual global cancer mortality ~34,000 Of which melanoma <80,000 deaths Lung 1,589,800 Liver Stomach 2,623,336 Colorectum 6,389 Breast 1,402 745,517 Oesophagus Pancreas 2,634
Slide 6: Tumor-directed immuno-oncology
Tumor-directed immuno-oncology GENERAL IMMUNE-ACTIVATION TUMOR-DIRECTED IMMUNE-ACTIVATION General immune activation is associated with risk of Selective activation of tumor-specific immune cells severe adverse effects results in systemic immunity with limited toxicity 6
Slide 7: Drug development pipeline
Drug development pipeline Partnered with co-developed with 7
Slide 8: ADC-1013 targeting CD40
ADC-1013 targeting CD40 ADC-1013 Mode of Action Immuno-modulating receptors ANTIGEN-PRESENTING CELL T CELL ANTIGEN-PRESENTING CELL T CELL ADC-1013 PDL1 or PDL2 ? + PDL1 or PDL2 PD1 – CD40 + CD80 or CD86 CD28 CD80 or CD86 CTLA4 – B7RP1 ICOS + B7-H3 ? – B7-H4 ? – HVEM BTLA – KIR – MHC class I or II TC
Slide 9: Immuno-oncology market and pipeline
Immuno-oncology market and pipeline Compound Company Indication Phase Target Yervoy® (ipilimumab) Bristol-Myers Squibb Melanoma M CTLA-4 > Approx. 70 immuno- Keytruda® (pembrolizumab) Opdivo® (nivolumab) Merck Bristol-Myers Squibb Melanoma, lung cancer, H&N cancer Melanoma, lung, renal, H&N, bladder
Slide 10: ADC-1013 first-in-human clinical phase I
ADC-1013 first-in-human clinical phase I ADC-1013 intratumoral dose escalation every 14 days to evaluate safety and tolerability in patients with advanced solid tumors Status: > Study completed March 2017, 24 patients enrolled > Five clinical centers in Sweden, Denmark and UK > Results presented at
Slide 11: Results ADC-1013 clinical phase I
Results ADC-1013 clinical phase I ADC-1013 is well tolerated by cancer > A second clinical phase I study is patients at clinically relevant doses ongoing, performed by Janssen Biotech, Inc. > Adverse events mainly low grade > > 50 patients enrolled to date and transient as expected > Intravenous dos
Slide 12: ATOR-1015: Dual binding to CTLA-4 and OX40
ATOR-1015: Dual binding to CTLA-4 and OX40 Design and optimization of the CTLA-4 binding part Anti-OX40 ATOR-1015 Anti-CTLA-4 5 mutations were introduced Affinity increased 100-fold T-cell DEPLETION OF Next generation CTLA-4 antibody REGULATORY T-CELLS with augmented Treg depletion ACTIVATION
Slide 13: ATOR-1015: In vivo synergy
ATOR-1015: In vivo synergy OX40 and CTLA-4 surrogate (mouse) antibodies 2,500 2,000 Tumor volume (mm³) 1,500 1,000 500 0 0 5 10 15 20 25 30 Time (days) Ctr IgG (right tumor) Ctr IgG (left tumor) OX40 and CTLA4 (right tumor) OX40 and CTLA4 (left tumor) Source: Hebb and Kohrt, American Society of hema
Slide 14: ATOR-1015 promotes cell-to-cell interactions
ATOR-1015 promotes cell-to-cell interactions F r a c tio n o f c e lls in c o m p le x e s ( % ) 20 15 A T O R -1 0 1 5 10 a n t i- O X 4 0 a n ti- C T L A - 4 5 m ix tu r e o f M a b s h Ig G 1 0 0 .0 0 1 0 .0 1 0 .1 1 10 100 C o n c (n M ) 14
Slide 15: ATOR-1015: In vitro synergy
ATOR-1015: In vitro synergy ATOR-1015 is superior to the combination of the two monospecific antibodies ATOR-1015 induces ADCC on CTLA-4/OX40 expressing T-reg Synergistic T-reg depletion 140 120 ADCC (fold induction) 100 80 T-reg 60 40 20 Macrophage 0 0.001 0.01 0.1 1 10 100 1000 > ATOR-1015 kills r
Slide 16: ATOR-1015: anti-tumor efficacy
ATOR-1015: anti-tumor efficacy Anti-tumor efficacy in multiple tumor models: bladder, colorectal, melanoma and pancreas Survival bladder cancer (MB49) Tumor-specific long-term immunity 100 250 ) 3 T u m o r v o lu m e ( m m 200 75 S u rv iv a l (% ) 150 50 100 25 50 0 0 0 40 80 120 0 10 20 30 T im e
Slide 17: Tumor-directed suppression of regulatory T cells
Tumor-directed suppression of regulatory T cells ATOR-1015 activates the immune system in tumors, but not elsewhere in the body ATOR-1015 increases Teff/Treg ratio in tumor ATOR-1015 does not affect systemic T-cells Colon carcinoma model C D 8 / T r e g r a t io s p le e n ( f o ld c h a n g e ) C D
Slide 18: ATOR-1015 positioning
ATOR-1015 positioning > Tumor-directed CTLA4 antibody with augmented T-reg depletion > First in class dual immune activator > Expected synergy with PD-1 > Excellent bispecific format > Clinical trial in cancer patients starts 2018 18
Slide 19: ATOR-1017 targeting 4-1BB
ATOR-1017 targeting 4-1BB > Best-in-class 4-1BB antibody > Strong efficacy due to efficient FcγR mediated crosslinking in the tumor > Tumor-directed T-cell activation enabling a superior safety profile > In preclinical development > Cell line development in progress > Clinical trial to start 2019 19
Slide 20: ALG.APV-527 targeting 4-1BB & 5T4
ALG.APV-527 targeting 4-1BB & 5T4 > Bispecific 5T4 tumor-directed 4-1BB antibody > In preclinical development > Co-development agreement signed 2017 with Aptevo Therapeutics, US - the companies will equally own and finance the development of the drug candidate through Phase II > Clinical trial to st
Slide 21: Financials Q1-Q3 2017
Financials Q1-Q3 2017 Actual Actual Actual (MSEK) Jan - Sep 2017 Jan – Sep 2016 FY 2016 Net Revenue 5.6 51.8 58.2 Net Loss -76.3 -29.0 -48.4 R&D expenses as % of total expenses 69.5% 62.2% 64.3% Liquidity incl bonds at end of the period 588 346 659 Equity per share, after dilution (SEK) 8.48 5.91 9.
Slide 22: Major shareholders as of December
Major shareholders as of December Shareholder Number of shares % of total shares Banque Internationale à Luxembourg SA 13 588 121 19.0 Janssen Biotech 5 762 523 8.1 Sunstone Life Science Ventures Fund II K/S 5 758 485 8.1 Lars Spånberg 3 213 858 4.5 Goldman Sachs & Co. 2 640 000 3.7 Atlas Antibodies
Slide 23: Experienced Management team
Experienced Management team Per Norlén Peter Ellmark Christina Furebring Charlotte A. Russell Per-Olof Schrewelius – born 1970, CEO since – born 1973, VP Discovery – born 1964, Senior Vice – born 1964, Chief Medical – born 1963, Chief 2015 – is a registered since 2018 – holds a President Research an
Slide 24: Strong immuno-oncology pipeline
Strong immuno-oncology pipeline CD-40 CTLA-4 x OX40 4-1BB 4-1BB x 5T4 N.D. x TNFR-SF 24
Slide 25: Alligator Bioscience
\ ALLIGATOR» bioscienc
Alligator Bioscience — Investor Presentation (January 2018) on 6ix